ConforMIS appoints Mark A. Augusti as CEO
The Company also expects that Mr. Augusti will be appointed to the Company’s Board of Directors following the commencement of his employment.
Mr. Augusti’s 27-year business career has been marked with executive management responsibility in medical technology sales, marketing and general management.
Mr. Augusti joined Integra LifeSciences Corporation (Integra) in April 2014 and is Integra's Corporate Vice President and President of Orthopedics and Tissue Technologies.
He served as Chief Executive Officer at Bioventus LLC, from May 2012 to August 2013, and was a member of the company's Board of Directors during the same period.
Prior to that Mr. Augusti spent nine years with Smith & Nephew Inc., from April 2003 to April 2012, in a series of leadership roles, including President of Smith & Nephew's Biologic Division, where he was appointed to lead Smith & Nephew's new biologics initiative.
Mr. Augusti also served as Smith & Nephew's President of the Orthopaedic Trauma & Clinical Therapies Global Business and Senior Vice President and General Manager of the Trauma business.
In 2000, he joined J.P. Morgan Securities as a Vice President in the Private Funds group.
From 1987 to 2000, he spent 13 years at GE Medical Systems Inc., where he held various sales, marketing and strategic management roles, both in the U.S. and internationally.
Mr. Augusti received his M.B.A. from the UCLA Anderson School of Management and his B.S. in Computer Science and Economics from Duke University. ■
LATEST MOVES FROM Massachusetts
- Haemonetics Corporation appoints Robert E. Abernathy to board
- Tetraphase Pharma appoints Kamalam Unninayar as CFO
- Boston Biomedical appoints Edgar Braendle as vice president
- Analogic Corporation appoints Joseph Whitters to board
- Eleven Biotherapeutics appoints Richard F. Fitzgerald as interim CFO
More inside POST
Korn Ferry Q1 diluted EPS $0.51 Earnings